CollPlant Bio's Collink.3D® Shows High Success in Bone Regeneration Study
Ticker: CLGN · Form: 6-K · Filed: Apr 15, 2025 · CIK: 1631487
Sentiment: bullish
Topics: clinical-trial, biotechnology, medical-devices, regenerative-medicine
TL;DR
CollPlant's Collink.3D® bio-ink study successful, 90% bone fusion rate in 20 patients.
AI Summary
On April 15, 2025, CollPlant Biotechnologies Ltd. announced the successful completion of a clinical study for its Collink.3D® bio-ink, demonstrating significant improvements in bone regeneration. The study involved 20 patients and showed a 90% success rate in achieving bone fusion within six months. This advancement is a key step towards potential commercialization and regulatory approval.
Why It Matters
This successful clinical trial for CollPlant's novel bio-ink brings them closer to potential market entry, offering a new therapeutic option for bone defects and injuries.
Risk Assessment
Risk Level: medium — While the clinical study results are positive, regulatory approval and market adoption are still uncertain, and the company faces ongoing development and commercialization risks.
Key Numbers
- 20 — Patients (Number of participants in the clinical study)
- 90% — Success Rate (Achieved bone fusion rate in the study)
- 6 months — Time to Fusion (Duration for bone fusion observed in the study)
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- Collink.3D® (product) — Bio-ink product
- April 15, 2025 (date) — Announcement date
FAQ
What was the primary outcome of the clinical study for Collink.3D®?
The clinical study demonstrated significant improvements in bone regeneration, with a 90% success rate in achieving bone fusion within six months for the 20 participating patients.
When was the press release regarding the clinical study results issued?
The press release was issued on April 15, 2025.
What is the specific product being highlighted in the filing?
The filing highlights CollPlant's Collink.3D® bio-inks and their application in a clinical study for bone regeneration.
What is the company's standard industrial classification?
The company's standard industrial classification is ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842].
What is the address of CollPlant Biotechnologies Ltd.'s principal executive office?
The address of the principal executive office is 4 Oppenheimer St, Weizmann Science Park Rehovot 7670104, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2025 regarding CollPlant Biotechnologies Ltd (CLGN).